Tirofiban

Pharmacologic Category

Antiplatelet Agent, Glycoprotein IIb/IIIa Inhibitor

Dosing: Adult

Unstable angina/non-ST-elevation myocardial infarction (UA/NSTEMI): IV: Loading dose: 25 mcg/kg administered over 5 minutes or less; Maintenance infusion: 0.15 mcg/kg/minute continued for up to 18 hours

Percutaneous coronary intervention (PCI): IV: Loading dose: 25 mcg/kg administered over 5 minutes or less at the time of PCI; Maintenance infusion: 0.15 mcg/kg/minute continued for up to 18 hours (ACCF/AHA/SCAI [Levine 2011]; Valgimigli 2004)

Stable ischemic heart disease (high-risk features) undergoing elective PCI (off-label use): Loading dose: 25 mcg/kg administered over 5 minutes or less at the time of PCI; Maintenance infusion: 0.15 mcg/kg/minute; was continued for up to 48 hours in the clinical trial (ACCF/AHA/SCAI [Levine 2011]; Valgimigli 2004). Note: Reserve for patients who were not pretreated with clopidogrel or who are undergoing elective PCI with stent implantation with adequate clopidogrel pretreatment (ACCF/AHA/SCAI [Levine 2011]).

ST-elevation myocardial infarction (STEMI) undergoing primary PCI (off-label use): IV Loading dose: 25 mcg/kg administered over 5 minutes or less at the time of PCI; Maintenance infusion: 0.15 mcg/kg/minute in combination with heparin or bivalirudin in selected patients; was continued for 18-24 hours in clinical trials (ACCF/AHA [O’Gara 2013]; ACCF/AHA/SCAI [Levine 2011]; Valgimigli 2008; Van’t Hof 2008)

* See Dosage and Administration in AHFS Essentials for additional information.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Renal Impairment: Adult

Note: Renal function may be estimated using the Cockcroft-Gault formula using actual body weight.

CrCl >60 mL/minute: No dosage reduction necessary.

CrCl ≤60 mL/minute: IV Loading dose: 25 mcg/kg administered over ≤5 minutes; Maintenance infusion: 0.075 mcg/kg/minute continued for up to 18 hours.

Hemodialysis: Dialyzable: Yes (NCS/SCCM [Frontera 2016])

Calculations

• Creatinine Clearance by Cockcroft-Gault
• Creatinine Clearance by Cockcroft-Gault (SI units)
• Creatinine Clearance by Cockcroft-Gault with IBW
• Creatinine Clearance by Cockcroft-Gault with IBW (SI units)

Use: Labeled Indications

Unstable angina/non-ST-elevation myocardial infarction: To decrease the rate of thrombotic cardiovascular events (combined end point of death, MI, or refractory ischemia/repeat cardiac procedure) in patients with non-ST-elevation acute coronary syndrome (unstable angina/non-ST-elevation myocardial infarction [UA/NSTEMI]).

* See Uses in AHFS Essentials for additional information.

Use: Off-Label: Adult

To support PCI (administered at the time of PCI) for ST-elevation myocardial infarction (STEMI)Level of Evidence [A, G]

Data from one double-blinded, randomized, controlled trial and one open-label, randomized, controlled trial supports the use of high-bolus dose tirofiban in the management of patients with STEMI undergoing primary PCI Ref.

Based on the American College of Cardiology Foundation/American Heart Association/Society for Cardiovascular Angiography and Interventions (ACCF/AHA/SCAI) guidelines for PCI and the ACCF/AHA guidelines for the management of STEMI, a glycoprotein IIb/IIIa inhibitor including tirofiban (high-bolus dose) given to support primary PCI is effective and recommended in the management of patients with STEMI undergoing primary PCI.

To support PCI (administered at the time of elective PCI) for stable ischemic heart disease (high risk features)Level of Evidence [B, G]

Data from a small, single-center, double-blind, placebo-controlled, randomized trial enrolling 202 patients with clinical or angiographic high-risk features (29% with stable angina) undergoing elective or urgent PCI supports the use of high-bolus dose tirofiban in the management of patients with stable ischemic heart disease and high risk features undergoing PCI Ref. Additional trials may be necessary to further define the role of tirofiban in this setting.

Based on the American College of Cardiology Foundation/American Heart Association/Society for Cardiovascular Angiography and Interventions (ACCF/AHA/SCAI) guidelines for PCI, a glycoprotein IIb/IIIa inhibitor including tirofiban (high-bolus dose) given to support elective PCI is effective and recommended in the management of patients with stable ischemic heart disease and high risk features undergoing PCI.

Level of Evidence Definitions

Level of Evidence Scale

Class and Related Monographs

Glycoprotein IIb/IIIa Inhibitors

Clinical Practice Guidelines

Coronary Artery Bypass Graft:

ACCF/AHA, “2011 Guideline for Coronary Artery Bypass Graft Surgery,” November 2011

Non-ST-Elevation Acute Coronary Syndromes:

AHA/ACC, "2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes,” September 2014.

Percutaneous Coronary Intervention:

ACCF/AHA/SCAI, “2011Guideline for Percutaneous Coronary Intervention,” November 2011

ST-Elevation Myocardial Infarction:

ACCF/AHA, “2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction,” December 2012.

Surgery:

STS, “2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,” November 2012

Administration: IV

Administer loading dose over 5 minutes or less, followed by a continuous infusion. Note: Clinical trials administered tirofiban loading dose over a period of 3 minutes (Valgimigli 2004; Valgimigli 2005; Valgimigli 2009).

Storage/Stability

Store at 25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F); do not freeze. Protect from light during storage. Discard any unused portion.

Preparation for Administration: Adult

Do not dilute. Determine the volume needed to administer the loading dose using the 15 mL (concentration: 250 mcg/mL) premixed bolus vial or the 100 mL premixed vial (concentration: 50 mcg/mL) or 250 mL premixed bag (concentration: 50 mcg/mL). Determine the infusion rate of the maintenance infusion using the 100 mL premixed vial or 250 mL bag; do not use bags in series connections.

Compatibility

See Trissel’s IV Compatibility Database

Open Trissel's IV Compatibility

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to lower the chance of heart attack, the need for some heart treatments, or blockage of a stent after a stent is placed in the heart.

• It may be given to you for other reasons. Talk with the doctor.

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• Bleeding like vomiting blood or vomit that looks like coffee grounds; coughing up blood; blood in the urine; black, red, or tarry stools; bleeding from the gums; abnormal vaginal bleeding; bruises without a reason or that get bigger; or any severe or persistent bleeding.

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

Medication Safety Issues

Sound-alike/look-alike issues:

High alert medication:

Contraindications

Severe hypersensitivity reaction (ie, anaphylactic reaction) to tirofiban or any component of the formulation; history of thrombocytopenia following prior exposure to tirofiban; active internal bleeding or a history of bleeding diathesis, major surgical procedure, or severe physical trauma within the previous month

Canadian labeling: Additional contraindications (not in US labeling): History of thrombocytopenia following prior exposure to any other GPIIb/IIIa inhibitor; recent (within the previous 30 days) internal bleeding; history of intracranial hemorrhage or neoplasm, arteriovenous malformation, or aneurysm; history, symptom or findings suggestive of aortic dissection; known coagulopathy, platelet disorder or history of thrombocytopenia; stroke within 30 days prior to hospitalization or any history of hemorrhagic stroke; major surgical procedure or relevant trauma within the previous 6 weeks; malignant or severe uncontrolled hypertension (>180 mmHg/110 mmHg); current use with other GP IIb/IIIa inhibitors; acute pericarditis; cirrhosis or clinically significant liver disease; angina precipitated by obvious provoking factors (eg, arrhythmia, severe anemia, hyperthyroidism, hypotension); recent epidural procedure.

Warnings/Precautions

Concerns related to adverse effects:

• Bleeding: The most common complication is bleeding, including retroperitoneal, pulmonary, and spontaneous GI and/or GU bleeding; watch closely for bleeding, especially the arterial access site for the cardiac catheterization. Fatal bleeding has been reported. Use with extreme caution in patients with platelet counts <150,000/mm3, patients with hemorrhagic retinopathy, previous history of GI disease, recent thrombolytic therapy and in chronic dialysis patients. Use caution with administration of other drugs affecting hemostasis. Minimize other procedures including arterial and venous punctures, IM injections, nasogastric tubes, etc.

• Thrombocytopenia: Profound thrombocytopenia has been reported with use of tirofiban. If during therapy platelet count decreases to <90,000/mm3, monitor platelet counts to exclude pseudothrombocytopenia. If thrombocytopenia is confirmed, discontinue tirofiban and heparin if administered concurrently. Platelet counts should recover rapidly (within 1 to 5 days) after discontinuation. Previous exposure to a glycoprotein IIb/IIIa inhibitor may increase the risk of thrombocytopenia. Use is contraindicated in patients with a history of thrombocytopenia following exposure to tirofiban. Specific management guidelines for GP IIb/IIIa induced thrombocytopenia have been published (Huxtable 2006; Llevadot 2000).

Disease-related concerns:

• Renal impairment: Dosage reduction of the maintenance infusion rate is necessary in patients with CrCl ≤60 mL/minute.

Other warnings/precautions:

• Percutaneous coronary intervention: Sheath removal: Prior to pulling the sheath, ACT should be <180 seconds or aPTT <50 seconds (ACCF/AHA/SCAI [Levine, 2011]). Use standard compression techniques after sheath removal. Watch the site closely afterwards for further bleeding.

• Surgery: Discontinue at least 2 to 4 hours prior to coronary artery bypass graft surgery (ACC/AHA [Amsterdam 2014]; ACCF/AHA [Hillis, 2011]).

* See Cautions in AHFS Essentials for additional information.

Geriatric Considerations

Elderly patients receiving tirofiban with heparin or heparin alone had a higher incidence of bleeding in clinical trials. Caution must be used when using other drugs affecting hemostasis, which are commonly used in elderly.

Pregnancy Considerations

Information related to use in pregnancy is limited (Boztosun 2008; Hajj-Chahine 2010).

Breast-Feeding Considerations

It is not known if tirofiban is present in breast milk.

According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.

Briggs' Drugs in Pregnancy & Lactation

• Tirofiban

Adverse Reactions

Bleeding is the major drug-related adverse effect. Patients received background treatment with aspirin and heparin. Adverse reactions reported are derived from both the high-dose bolus regimen and the dosing regimen used in studies that established the effectiveness of tirofiban. Frequency not always defined.

>10%: Hematologic & oncologic: Minor hemorrhage (TIMI criteria minor bleeding; 10.5% to 12%; transfusion required: 4% to 4.3%)

1% to 10%:

Cardiovascular: Coronary artery dissection (5%), bradycardia (4%), edema (2%), vasodepressor syncope (2%)

Central nervous system: Dizziness (3%), headache (>1%)

Dermatologic: Diaphoresis (2%)

Gastrointestinal: Nausea (>1%)

Genitourinary: Pelvic pain (6%)

Hematologic & oncologic: Major hemorrhage (TIMI criteria major bleeding: 1.4% to 2.2%; including hematoma [femoral]: 2% [Valgimigli 2005], intracranial bleeding, GI bleeding, retroperitoneal bleeding [Aydin 2003], GU bleeding, pulmonary alveolar hemorrhage [Guo 2012], spinal-epidural hematoma), thrombocytopenia: <90,000/mm3 (1.5% to 1.9%), <50,000/mm3 (0.3% to 0.5%)

Neuromuscular & skeletal: Leg pain (3%)

Miscellaneous: Fever (>1%)

<1%, postmarketing, and/or case reports: Anaphylaxis, hemopericardium, hypersensitivity, skin rash, urticaria

* See Cautions in AHFS Essentials for additional information.

Allergy and Idiosyncratic Reactions

• Glycoprotein (GP) IIb/IIIa Inhibitor Allergy

Metabolism/Transport Effects

None known.

Drug Interactions Open Interactions

Acalabrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties. Risk C: Monitor therapy

Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. Exceptions: Bemiparin; Enoxaparin; Heparin. Risk C: Monitor therapy

Apixaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased. Management: Carefully consider risks and benefits of this combination and monitor closely. Risk C: Monitor therapy

Bemiparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Bemiparin. Management: Avoid concomitant use of bemiparin with antiplatelet agents. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding. Risk D: Consider therapy modification

Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. Risk C: Monitor therapy

Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. Risk C: Monitor therapy

Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel. Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor. Risk C: Monitor therapy

Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs. Risk C: Monitor therapy

Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. Risk C: Monitor therapy

Edoxaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. Risk C: Monitor therapy

Enoxaparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Enoxaparin. Management: Discontinue antiplatelet agents prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding. Risk D: Consider therapy modification

Fat Emulsion (Fish Oil Based): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Heparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Heparin. Management: Decrease the dose of heparin or agents with antiplatelet properties if coadministration is required. Risk D: Consider therapy modification

Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur. Management: Avoid combination when possible. If used, monitor more closely for evidence of bleeding. Discontinue herbal products with anticoagulant or antiplatelet actions 2 weeks prior to surgical, dental, or invasive procedures. Risk D: Consider therapy modification

Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. Risk C: Monitor therapy

Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Inotersen: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. Risk C: Monitor therapy

Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents. Risk C: Monitor therapy

Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban. Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor. Risk C: Monitor therapy

Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result. Risk C: Monitor therapy

Selumetinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. Risk C: Monitor therapy

Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. Risk X: Avoid combination

Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Zanubrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties. Risk C: Monitor therapy

Genes of Interest

• Integrin Subunit Beta 3

Monitoring Parameters

Platelet count (baseline; 6 hours after initiation and daily thereafter during therapy). Monitor platelet counts more closely in patients who have had previous exposure to glycoprotein IIb/IIa antagonists. Persistent reductions of platelet counts <90,000/mm3 may require interruption or discontinuation of infusion; hemoglobin and hematocrit; signs of bleeding.

Standard post-PCI assessment if patient undergoes PCI (eg, monitoring vascular access site, monitoring for chest pain and signs of bleeding)

Advanced Practitioners Physical Assessment/Monitoring

Monitor vital signs prior to, during, and after therapy. Assess infusion insertion site during and after therapy. Monitor closely for bleeding and teach bleeding precautions. Monitor platelet count 6 hours after initiation of infusion then daily thereafter. Reduce dose in patients with severe renal insufficiency.

Nursing Physical Assessment/Monitoring

Monitor vital signs prior to, during, and after therapy. Assess infusion insertion site during and after therapy (every 15 minutes or as institutional policy). Monitor closely for unusual or excessive bleeding (eg, CNS changes; blood in urine, stool, or vomitus; unusual bruising or bleeding). Monitor platelet counts.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Concentrate, Intravenous:

Aggrastat: 3.75 mg/15 mL (15 mL)

Solution, Intravenous:

Aggrastat: 5 mg/100 mL in NaCl 0.9% (100 mL); 12.5 mg/250 mL in NaCl 0.9% (250 mL)

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous:

Aggrastat: 12.5 mg/250 mL in NaCl 0.9% (250 mL)

Anatomic Therapeutic Chemical (ATC) Classification

• B01AC17

Generic Available (US)

No

Pricing: US

Concentrate (Aggrastat Intravenous)

3.75 mg/15 mL (per mL): $17.80

Solution (Aggrastat Intravenous)

5 mg/100 mL 0.9% (per mL): $2.97

12.5MG/250ML 0.9% (per mL): $2.49

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

A reversible antagonist of fibrinogen binding to the glycoprotein (GP) IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation. When administered intravenously, it inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. When given according to the recommended regimen, >90% inhibition is attained within 10 minutes after initiation. Platelet aggregation inhibition is reversible following cessation of the infusion.

Pharmacodynamics/Kinetics

Onset: >90% inhibition of platelet aggregation (reversible after discontinuation) seen within 10 minutes

Distribution: Vdss: 22 to 42 L

Protein Binding: 65% (concentration dependent)

Metabolism: Negligible

Half-life elimination: 2 hours; Note: In ~90% of patients, ex vivo platelet aggregation returns to near baseline in 4 to 8 hours after discontinuation.

Excretion: Urine (65%) and feces (25%) primarily as unchanged drug

Pharmacodynamics/Kinetics: Additional Considerations

Renal function impairment: Plasma clearance is decreased by ~40% in patients with CrCl <60 mL/minute and more than 50% in patients with CrCl <30 mL/minute (including those requiring hemodialysis).

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Effects on Dental Treatment

Key adverse event(s) related to dental treatment: Bleeding is a potential adverse effect of tirofiban. See Effects on Bleeding.

Effects on Bleeding

As with all anticoagulants, bleeding is a potential adverse effect of tirofiban during dental surgery; risk is dependent on multiple variables, including the intensity of anticoagulation and patient susceptibility. Medical consult is suggested. It is unlikely that ambulatory patients presenting for dental treatment will be taking intravenous anticoagulant therapy.

Related Information

• Glycoprotein Antagonists

Index Terms

MK383; Tirofiban Hydrochloride

FDA Approval Date

May 14, 1998

References

Aggrastat (tirofiban) [prescribing information]. Somerset, NJ: Medicure Pharma; May 2019.

Aggrastat (tirofiban) [product monograph]. Oakville, Ontario, Canada: Cipher Pharmaceuticals Inc; July 2019.

“A Comparison of Aspirin Plus Tirofiban With Aspirin Plus Heparin for Unstable Angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators,” N Engl J Med, 1998, 338(21):1498-505.[PubMed 9599104]

Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in J Am Coll Cardiol. 2014;64(24):2713-2714]. J Am Coll Cardiol. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017.[PubMed 25260718]

Aydin M, Ozeren A, Bilge M, Gursurer M, Ozdemir H, Savranlar A. Retroperitoneal hematoma following tirofiban and enoxaparin coadministration in a patient with acute coronary syndrome. Thromb Res. 2003;111(1-2):121-123.[PubMed 14644090]

Boztosun B, Olcay A, Avci A, et al, "Treatment of Acute Myocardial Infarction in Pregnancy With Coronary Artery Balloon Angioplasty and Stenting: Use of Tirofiban and Clopidogrel," Int J Cardiol, 2008, 127(3):413-6.[PubMed 17655948]

Brener SJ, Barr LA, Burchenal JE, et al, “Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial Infarction,” ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators, Circulation, 1998, 98(8):734-41.

Cannon CP, Weintraub WS, Demopoulos LA, et al, “Comparison of Early Invasive and Conservative Strategies in Patients With Unstable Coronary Syndromes Treated With the Glycoprotein IIb/IIIa Inhibitor Tirofiban,” N Engl J Med, 2001, 344(25):1879-87.[PubMed 11419424]

Demirkan B, Guray Y, Guray U, et al, “Differential Diagnosis and Management of Acute Profound Thrombocytopenia by Tirofiban: A Case Report,” J Thromb Thrombolysis, 2006, 22(1):77-8.[PubMed 16786237]

“Effects of Platelet Glycoprotein IIb/IIIa Blockade With Tirofiban on Adverse Cardiac Events in Patients With Unstable Angina or Acute Myocardial Infarction Undergoing Coronary Angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis,” Circulation, 1997, 96(5):1445-53.[PubMed 9315530]

Ferraris VA, Saha SP, Oestreich JH, et al, “2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,” Ann Thorac Surg, 2012, 94(5):1761-81.[PubMed 23098967]

Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care. 2016;24(1):6-46.[PubMed 26714677]

Giugliano RP, White JA, Bode C, et al, “Early Versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes,” N Engl J Med, 2009, 360(21):2176-90.[PubMed 19332455]

Guo J, Xu M, Xi Y. Tirofiban-induced diffuse alveolar hemorrhage: after primary angioplasty. Tex Heart Inst J. 2012;39(1):99-103.[PubMed 22412240]

Hajj-Chahine J, Jayle C, Tomasi J, et al. Successful surgical management of massive pulmonary embolism during the second trimester in a parturient with heparin-induced thrombocytopenia. Interact Cardiovasc Thorac Surg. 2010;11(5):679-681. doi: 10.1510/icvts.2010.247460.[PubMed 20729238]

Hillis LD, Smith PK, Anderson JL, et al, “2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” Circulation, 2011, 124(23):2610-42.[PubMed 22064600]

Huxtable LM, Tafreshi MJ, and Rakkar AN, “Frequency and Management of Thrombocytopenia With the Glycoprotein IIb/IIIa Receptor Antagonists,” Am J Cardiol, 2006, 97(3):426-9.[PubMed 16442410 ]

“Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor With Tirofiban in Unstable Angina and Non-Q-Wave Myocardial Infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators,” N Engl J Med, 1998, 338(21):1488-97.[PubMed 9599103]

Levine GN, Bates ER, Blankenship JC, et al, “2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,” Circulation, 2011, 124(23):e574-651.[PubMed 22064601]

Lincoff AM, Califf RM, Moliterno DJ, et al, “Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators,” N Engl J Med, 1999, 341(5):319-27.[PubMed 10423466]

Llevadot J, Coulter SA, and Giugliano RP, “A Practical Approach to the Diagnosis and Management of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Receptor Inhibitors,” J Thromb Thrombolysis, 2000, 9(2):175-80.[PubMed 10613999]

O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in Circulation. 2013;128(25):e481.] Circulation. 2013;127(4):e362-e425.[PubMed 23247304]

Topol EJ, Moliterno DJ, Herrmann HC, et al, “Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events With Percutaneous Coronary Revascularization,” N Engl J Med, 2001, 344(25):1888-94.[PubMed 11419425]

Valgimigli M, Campo G, de Cesare N, et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention. Circulation. 2009;119:3215-3222.[PubMed 19528337]

Valgimigli M, Campo G, Percoco G, et al, “Comparison of Angioplasty With Infusion of Tirofiban or Abciximab and With Implantation of Sirolimus-eluting or Uncoated Stents for Acute Myocardial Infarction: the MULTISTRATEGY Randomized Trial,” JAMA, 2008, 299(15):1788-99.[PubMed 18375998]

Valgimigli M, Percoco G, Barbieri D, et al, “The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty, J Am Coll Cardiol, 2004, 44(1):14-9.[PubMed 15234398]

Valgimigli M, Percoco G, Malagutti P, et al, “Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction: A Randomized Trial,” JAMA, 2005, 293(17):2109-17.[PubMed 15870414]

Van’t Hof AW, ten Berg J, Heestermans T, et al, “Prehospital Initiation of Tirofiban in Patients with ST-elevation Myocardial Infarction Undergoing Primary Angioplasty (On-TIME 2): A Multicenter, Double-Blind, Randomized Controlled Trial,” Lancet, 2008, 372(9638):537-46.[PubMed 18707985]

Brand Names: International

Aggrastat (AE, AT, AU, BB, BE, BG, BH, BM, BS, BZ, CH, CN, CY, CZ, DE, DK, EE, EG, FI, GB, GR, GY, HK, HU, IL, IN, IT, JM, JO, LB, LT, LU, LV, MT, MY, NL, NZ, PH, PK, PL, PR, PT, QA, SA, SE, SG, SI, SR, TR, TT, TW); Agrastat (AR, BR, CL, CO, CR, EC, ES, FR, GT, HN, KR, MX, NI, PA, PE, SV, UY, VE); Eupifiban (EG); Sunnycardio (EG); Tiroprest (LB)

Last Updated 4/22/20